Guidelines for the management of asthma
Below is a list of links to the most recent guidelines for asthma management. While
details may vary, guidelines emphasize an aggressive anti-inflammatory approach,
regular physician follow-up, and attention to asthma triggers, all of which are
necessary to gain and maintain long-term control of persistent asthma.
NOTE: These Web sites are external to
AstraZeneca. AstraZeneca does not possess editorial control of their content, and
no endorsement, expressed or implied, is intended.
National Heart, Lung, and Blood Institute,
Guidelines for the Diagnosis and Management of Asthma (EPR-3) published
in 2007 by the National Asthma Education and Prevention Program (NAEPP) of the NHLBI.
This was the first update of national guidelines in a decade. The guidelines emphasize
the importance of asthma control and include updated recommendations for managing
asthma including an expanded section on childhood asthma.
The Joint Task Force on Practice Parameters,
Attaining Optimal Asthma Control: A Practice Parameter published in 2005
by a committee representing the American Academy of Allergy, Asthma & Immunology
(AAAAI), the American College of Allergy, Asthma & Immunology (ACAAI), and the
Joint Council of Allergy, Asthma, and Immunology (JCAAI).
This report builds upon the NAEPP report published in 1991 and provides recommendations
in the form of summary statements accompanied by grades of recommendations and levels
AAAAI—American Academy of Allergy, Asthma & Immunology
AAP—American Academy of Pediatrics
ACAAI—American College of Allergy, Asthma & Immunology
ACCP—American College of Chest Physicians
ARIA—Allergic Rhinitis and Its Impact on Asthma
JCAAI—Joint Council of Allergy, Asthma and Immunology
NAEPP—National Asthma Education and Prevention Program
NHLBI—National Heart, Lung, and Blood Institute
NIH—National Institutes of Health
IMPORTANT SAFETY INFORMATION ABOUT PULMICORT
PULMICORT RESPULES is not a bronchodilator and is NOT indicated for the relief of
Particular care is needed for patients who are transferred from systemically active
corticosteroids to PULMICORT RESPULES, because deaths due to adrenal insufficiency
have occurred in asthmatic patients during and after transfer from systemic corticosteroids
to less systemically available inhaled corticosteroids.
It is possible that systemic corticosteroid effects such as hypercorticism, reduced
bone mineral density, and adrenal suppression may appear in a small number of patients,
particularly at higher doses.
Patients taking immunosuppressant doses of corticosteroids should avoid exposure
to infections such as chicken pox and measles.
Inhaled corticosteroids may cause a reduction in growth velocity. The long-term
effect on final adult height is unknown.
Hypersensitivity reactions, including anaphylaxis, have been reported with budesonide.
As with other inhaled medications, paradoxical bronchospasm may occur with
In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic
conditions and clinical features consistent with Churg-Strauss Syndrome.
Adverse reactions that occurred at a rate of ≥ 3% are: respiratory infection, rhinitis, coughing, otitis media, viral infection, moniliasis, gastroenteritis, vomiting, diarrhea, abdominal pain, ear infection, epistaxis, conjunctivitis, and rash.
PULMICORT RESPULES (budesonide inhalation suspension) is indicated for the maintenance
treatment of asthma and as prophylactic therapy in children ages 12 months to 8 years.
for full Prescribing Information for PULMICORT RESPULES.
You are encouraged to report negative side effects of prescription
drugs to the FDA.
Visit www.FDA.gov/medwatch or call